Review Article

ERA'S JOURNAL OF MEDICAL RESEARCH VOL.11 NO.1

DOI: 10.24041/ejmr2024.11

RED CELL FRAGMENTATION SYNDROME: A REVIEW

Reeta Chaudhary[1], Shivangi Shukla[1], Huma Parveen[1], Saba Naziya[2]

Department of Pathology

United Institute of Medical Sciences, Allahabad, U.P., India-231313.[2]

Era's Lucknow Medical College and Hospital, Era University, Sarfarazganj, Lucknow, U.P., India-226003.[1]

Received on : 18-02-2024
Accepted on : 09-06-2024

Address for correspondence

Dr. Reeta Chaudhary
Department of Pathology
Era's Lucknow Medical College & Hospital, Era University, Lucknow-226003.
Email: dr.reetachaudhary@gmail.com
Contact no: +91-9557131674

ABSTRACT

Hemolytic anemia and perhaps fatal consequences can result from red cell fragmentation syndrome, a disorder marked by the fragmentation of red blood cells. This syndrome can occur due to various underlying causes, including abnormalities of the heart, blood vessels, or vascular malformations. This review aims to discuss the current understanding of red cell fragmentation syndrome, its causes, and its management. In this review, we will discuss the current understanding of red cell fragmentation syndrome, its causes, and its management.

KEYWORDS: Red cell fragmentation, Subclavian catheterization, Vascular malformation, Hemolytic anemia.

INTRODUCTION

Hemolytic anemia and sometimes fatal consequences can result from the complicated illness known as red cell fragmentation syndrome, which is defined by the fragmentation of red blood cells. Numerous underlying factors, including as cardiac defects, blood vessel problems, or vascular malformations, might result in this illness. When fragmented red cells (FRC) are seen in peripheral blood, red cell fragmentation syndrome is usually diagnosed. The prognosis varies according to the severity of the illness and the efficacy of treatment, and the management of the syndrome is contingent upon the underlying cause.

In this review, we will discuss the current understanding of red cell fragmentation syndrome, its causes, and its management. We will also discuss the clinical presentation, diagnosis, and management of the syndrome in different patient populations, including those with hemodialysis catheters, vascular malformations, and mitral valve disease.

Causes of Red Cell Fragmentation Syndrome

Red cell fragmentation syndrome is frequently caused by using single-lumen subclavian hemodialysis catheters. These catheters can cause partial occlusion of the catheter tip, leading to turbulent flow and high shear stress on the red blood cells, resulting in fragmentation and hemolysis.(1,2) The syndrome has been observed in patients undergoing hemodialysis, and its resolution has been reported after withdrawal of the catheter.

Another significant cause of red cell fragmentation syndrome is the presence of vascular malformations, such as arteriovenous malformations (AVMs). Patients with AVMs can develop red cell fragmentation due to the abnormal blood flow and high shear stress within the malformation (3,4,5). Similarly, patients with mitral valve disease can develop red cell fragmentation due to turbulent flow across the valve (3-6).

In addition to hemodialysis catheters and vascular malformations, red cell fragmentation syndrome can also occur in the context of thrombotic microangiopathy linked with transplantation (TA-TMA). A disorder known as TA-TMA can arise in recipients of allogeneic stem cell transplants, and it is characterized by the fragmentation of red blood cells, hemolytic anemia, and other systemic complications (3).

In cases of red cell fragmentation in microcirculation, it is referred as microangiopathic hemolytic anemia. The three main conditions that cause microangiopathic hemolytic anemia are disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome (7-8).

Some other causes of red cell fragmentation are: a) HELLP syndrome, b) march hemoglobinuria, c) disseminated malignancy and d) Kasbach- Merritt phenomenon (7-8).

Clinical Presentation

Red cell fragmentation syndrome can manifest clinically in a variety of ways, depending on the underlying reason. Anemia symptoms, including weakness, exhaustion, and dyspnea, might manifest in patients.

Along with it signs of hemolysis like reticulocytosis, increase bilirubin, increase in serum lactate

dehydrogenase, decreased haptoglobin and on peripheral blood smear evidence of schistocytes (7-8). They may also experience symptoms related to the underlying cause, such as chest pain or palpitations in patients with mitral valve disease (1,3-5).

Patients using hemodialysis catheters may get hemolytic anemia symptoms as a result of red cell fragmentation.

Similarly, patients with vascular malformations or mitral valve disease may present with signs and symptoms of hemolytic anemia, including fatigue, weakness, and shortness of breath (1,3-5).

In addition to the hemolytic anemia signs and symptoms, patients with TA-TMA may also show a wider variety of symptoms, such as renal impairment, neurological problems, and multi-organ involvement (3).

Diagnosis

Red cell fragmentation syndrome is usually diagnosed by looking for fragmented red cells (FRC), also known as schistocytes, in the peripheral blood. FRC can be identified using automated hematology analyzers, which can detect the fragmented cells based on their size and shape (1-2,9).

The presence of FRC is an important diagnostic criterion for several conditions associated with red cell fragmentation syndrome, including TA-TMA. In TA-TMA, the detection of FRC, along with other laboratory findings such as elevated lactate dehydrogenase (LDH) and decreased haptoglobin, is crucial for establishing the diagnosis (3).

In addition to the detection of FRC, other laboratory tests may be performed to support the diagnosis of red cell fragmentation syndrome, such as evaluating the degree of hemolysis (e.g., LDH, haptoglobin, indirect bilirubin) and assessing the underlying cause (e.g., coagulation studies, echocardiography for mitral valve disease, imaging for vascular malformations) (1-4).



***Fig. 1: Lichtman's Atlas of Hematology* (7)**

S. no.	Cause	Description	Symptoms	Management	Prognosis
1	Hemodialysis Catheters	Partial catheter occlusion by thrombus or clot	Hemolytic anemia, fatigue, weakness	Withdrawal of catheter	Reversible
2	Vascular Malformations	Abnormal blood flow and high shear stress	Hemolytic anemia, fatigue, weakness	Interventional procedures or surgical resection	Good if treated effectively
3	Mitral Valve Disease	Turbulent flow across the valve	Hemolytic anemia, fatigue, weakness	Surgical mitral valve replacement or repair	Good if treated effectively
4	TA-TMA	Thrombotic microangiopathy	Hemolytic anemia, fatigue, weakness	Supportive care, immunosuppressive therapy	Poor if not treated promptly

Management

The management of red cell fragmentation syndrome depends on the underlying cause of the condition.

In patients with hemodialysis catheters, the primary management strategy is the withdrawal of the catheter, which often resolves the syndrome (1-2,9). This approach addresses the root cause of the fragmentation, which is the partial occlusion and turbulent flow associated with the catheter.

For patients with vascular malformations, the management may involve interventional procedures, such as embolization or surgical resection of the malformation. These treatments aim to address the abnormal blood flow and high shear stress within the vascular malformation, which are the underlying causes of the red cell fragmentation (3,4-5).

In patients with mitral valve disease, the management may involve surgical mitral valve replacement or repair. This approach aims to correct the turbulent flow across the valve, which is the primary driver of the red cell fragmentation (3,4-5).

For patients with TA-TMA, the management typically involves a multifaceted approach, including supportive care (e.g., transfusions, antibiotics) and immunosuppressive therapy to prevent further complications. Prompt recognition and treatment of TA-TMA are crucial, as the prognosis can be poor if the syndrome is not addressed effectively (3).

Prognosis

The prognosis for patients with red cell fragmentation syndrome depends on the underlying cause and the severity of the syndrome.

In patients with hemodialysis catheters, the syndrome is often reversible after withdrawal of the catheter, and the prognosis is generally good.(1,2) This is because the primary cause of the fragmentation, the partial occlusion and turbulent flow associated with the catheter, is addressed by removing the catheter.

For patients with vascular malformations, the prognosis is generally good if the malformation is successfully treated with interventional procedures or surgical resection. This is because addressing the abnormal blood flow and high shear stress within the malformation can resolve the red cell fragmentation (3,4-5).

In patients with mitral valve disease, the prognosis is generally good if the valve is successfully repaired or replaced, as this can address the turbulent flow across the valve and resolve the red cell fragmentation (3,4-5).

However, the prognosis for patients with TA-TMA can be poor if the syndrome is not treated promptly and effectively. TA-TMA is a serious condition that can lead to multi-organ dysfunction and life-threatening complications if not managed appropriately (3).

CONCLUSION

A complicated disorder called red cell fragmentation syndrome causes red blood cells to break apart, which can result in hemolytic anemia and other potentially fatal consequences. The syndrome can occur due to various underlying causes, including the use of hemodialysis catheters, vascular malformations, mitral valve disease, and transplant-associated thrombotic microangiopathy.

Red cell fragmentation syndrome is usually diagnosed by looking for fragmented red blood cells in peripheral blood; the underlying cause will determine how the condition is managed. The prognosis can change depending on the severity of the syndrome and how well the treatment works, thus it is imperative to identify the underlying condition as soon as possible and treat it appropriately.

By understanding the current knowledge on red cell fragmentation syndrome, healthcare providers can better identify, diagnose, and manage this condition, ultimately improving patient outcomes and reducing the risk of life-threatening complications.

REFERENCES

1. Ballas SK, Marcolina MJ. Red cell fragmentation syndrome. Hematology. 2000;5(1):35-44.
2. Berns JS, O'Neill WC. Red cell fragmentation hemolysis in hemodialysis patients with silicone-coated single-lumen subclavian catheters. Am J Kidney Dis. 1992;19(5):420-423.
3. Regueiro A, Campelo-Parada F, Bosch J, et al. Red blood cell fragmentation after MitraClip implantation. JACC Cardiovasc Interv. 2016;9(5):e47-e48.
4. Abourjaili G, Torbey E, Alsaghir T, et al. Hemolytic anemia following mitral valve repair: a case presentation and literature review. Exp Clin Cardiol. 2012;1:248-250.
5. Yokoyama H, Mizuno S, Saito S. Subacute hemolytic anemia after transcatheter edge-to-edge mitral valve repair: a case report. Catheter Cardiovasc Interv. 2020;95:1230-1234.
6. Jodele S, Laskin BL, Dandoy CE, et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev. 2015;29(3):191-204.
7. Hematology-Oncology, Medical Education.

Hematology-Oncology: Medical Education. Available from: https://hemonc.mhmedical.com/Content.aspx?bookid=1889&sectionid=137388089. Accessed June 17, 2024.

8. Fragmentation Hemolytic anemia. In: Williams Hematology,9th edition. AccessMedicine. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=1581&sectionid=94305464. Accessed June 17, 2024.
9. Grosse-Brockhoffe F, Gehrman D. Mechanical hemolysis in patients with valvular heart disease and valve prosthesis. Am Heart J. 1976;74:137-144.

Orcid ID:

Reeta Chaudhary - https://orcid.org/0000-0003-4861-8806

Shivangi Shukla - https://orcid.org/0000-0002-4707-4475

Huma Parveen - https://orcid.org/0000-0001-5903-0130

Saba Naziya - https://orcid.org/0000-0003-0588-6034

How to cite this article:

Chaudhary R., Shukla S., Parveen H., Naziya S. Red Cell Fragmentation Syndrome: A Review. Era J. Med. Res. 2024; 11(1): 67-70.